Sanofi's shortlist of CEO candidates so far has a distinct French accent

Sanofi is putting together a short list of candidates to see who will take Chris Viehbacher's place as the next CEO, and not surprisingly there's a distinct French accent to the names being bounced around just now. Smith & Nephew's Olivier Bohuon, a high-profile French businessman, is back in circulation in Bloomberg's fresh take today. And Takeda's Christophe Weber, the former CEO of GSK-France also makes the list, ironically after running into a considerable amount of flak in Japan for not being sufficiently Japanese. Novartis's Eric Cornut, currently the chief ethics officer but someone who also did a stint as CEO of French division, cited. Cornut got his doctoral degree in Basel. And Bayer's Olivier Brandicourt, chairman of the healthcare executive committee, is a French national with a master's degree in biology from University of Paris. Some analysts have already suspected that the unusual showdown between Sanofi's board and Viehbacher signalled a shift in the company's focus back to France. If that translates into a provincial attitude, though, you can expect a sharp kickback from some longtime observers. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.